Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients

• Verfasst von: Billing, Heiko [VerfasserIn]
• Verfasst von: Sander, Anja [VerfasserIn]
• Verfasst von: Süsal, Caner [VerfasserIn]
• Verfasst von: Ovens, Jörg [VerfasserIn]
• Verfasst von: Feneberg, Reinhard [VerfasserIn]
• Verfasst von: Höcker, Britta [VerfasserIn]
• Verfasst von: Opelz, Gerhard [VerfasserIn]
• Verfasst von: Tönshoff, Burkhard [VerfasserIn]
• Titel: Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients
• Verf.angabe: Heiko Billing, Anja Sander, Caner Süsal, Jörg Ovens, Reinhard Feneberg, Britta Höcker, Karel Vondrak, Ryszard Grenda, Stybjorn Friman, David V. Milford, Mihai Lucan, Gerhard Opelz and Burkhard Tönshoff
• Jahr: 2013
• Umfang: 8 S.
• Fussnoten: Gesehen am 26.07.2018 ; Published online: 31 December 2012
• Titel Quelle: Enthalten in: Transplant international
• Ort Quelle: Lausanne : Frontiers Media, 1988
• Jahr Quelle: 2013
• Band/Heft Quelle: 26(2013), 3, Seite 331-338
• ISSN Quelle: 1432-2277
• DOI: doi:10.1111/tri.12049
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: biopsy-proven acute rejection
• Sach-SW: human leukocyte antigen antibodies
• Sach-SW: pediatric renal transplantation
• Sach-SW: soluble CD30
• Sach-SW: steroid-free immunosuppression
• K10plus-PPN: 1577963814

Abstract

Biomarker-based post-transplant immune monitoring for the prediction of impending graft rejection requires validation in specific patient populations. Serum of 28 pediatric renal transplant recipients within the framework of a well-controlled prospective randomized trial was analyzed pre- and post-transplant for soluble CD30 (sCD30), a biomarker reflecting mainly T-cell reactivity, and anti-human leukocyte antigen (anti-HLA) antibody reactivity, a biomarker for B-cell activation. A sCD30 concentration ≥40.3 U/ml on day 14 was able to discriminate between patients with or without biopsy-proven acute rejection (BPAR) with a sensitivity of 100% and a specificity of 76%. Six of seven patients (86%) with BPAR showed a sCD30 above this cut-off, whereas only 3/21 patients (14%) without BPAR had a sCD30 above this cut-off (P = 0.004). For pre- and post-transplant anti-HLA class II reactivities by enzyme-linked immunosorbent assay, a cut-off value of 140 optical density was able to discriminate rejecters from nonrejecters with a sensitivity of 86% or 71% and a specificity of 81% or 90%, respectively. Withdrawal of steroids was associated with a approximately twofold higher serum sCD30 compared to controls, but did not affect anti-HLA reactivities. An increased post-transplant sCD30 serum concentration and positive pre- and post-transplant anti-HLA class II reactivities are informative biomarkers for impending BPAR in pediatric renal transplant recipients. (TWIST, Clinical Trial No: FG-506-02-43)